{
  "ticker": "IBX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02970300",
  "id": "02970300",
  "pages": 8,
  "price_sensitive": false,
  "date": "20250717",
  "time": "1644",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250717/pdf/06lwv172s6c5sr.pdf",
  "summary": "### Summary: Change of Director\u2019s Interest Notice (Appendix 3Y)  \n\n#### **Key Points**:  \n- **Director 1: Robert Romeo Proulx**  \n  - **New Issuance**: 2,000,000 Unlisted Options (exercise price: $0.012, expiry: 29 May 2030).  \n  - Vesting conditions: Tied to clinical milestones (IND submission, Phase 2 study initiation/completion, regulatory approval for second agent).  \n  - **No change** to existing holdings:  \n    - 1,404,082 Ordinary Shares.  \n    - 2,000,000 Performance Rights (expiring 2028, tied to share price/market cap hurdles).  \n\n- **Director 2: Brett Mitchell**  \n  - **New Issuance**: 2,000,000 Unlisted Options (exercise price: $0.019, expiry: 29 May 2028).  \n  - Vesting: 1/3 immediately, 1/3 after 1 year, 1/3 after 2 years.  \n  - **No change** to existing holdings:  \n    - 4,270,908 Ordinary Shares.  \n    - 1,250,000 Performance Rights (expiring 2028, tied to share price/market cap hurdles).  \n\n- **Context**: Options issued per shareholder approval at AGM (30 May 2025). Zero consideration paid.  \n\n#### **Impact**:  \n- Potential dilution from 4M new options (subject to vesting).  \n- Aligns director incentives with clinical/regulatory milestones.  \n\n**No material trading or capital structure changes identified beyond director option grants.**",
  "usage": {
    "prompt_tokens": 3251,
    "completion_tokens": 352,
    "total_tokens": 3603,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-17T07:00:13.910650"
}